Meta-analysis of safety and efficacy of rolapitant, NK-1 receptor antagonist for prevention of chemotherapy-induced nausea and vomiting

H Ahmed, AM Hammad, AI Abushouk, M Zidan… - Current problems in …, 2018 - Elsevier
Although chemotherapeutic agents represent a cornerstone of cancer treatment,
chemotherapy-induced nausea and vomiting (CINV) affect the patients' quality of life and …
被引用次数：11 相关文章 所有 4 个版本

Phase 3 trial results for rolapitant, a novel NK-1 receptor antagonist, in the prevention of chemotherapy-induced nausea and vomiting (CINV) in subjects receiving …

BL Rapoport, A Poma, ML Hedley, RE Martell… - 2014 - ascopubs.org
9638 Background: Rolapitant is a highly selective competitive long acting NK-1 receptor
antagonist that demonstrated efficacy and safety in a large randomized phase 2 dose …
被引用次数：15 相关文章

Phase 3 trial results for rolapitant, a novel NK-1 receptor antagonist, in the prevention of chemotherapy-induced nausea and vomiting (CINV) in subjects receiving …

ID Schnadig, MR Modiano, A Poma, ML Hedley… - 2014 - ascopubs.org
9633 Background: Rolapitant is a highly selective competitive long acting NK-1 receptor
antagonist that demonstrated efficacy in a large randomized phase 2 dose-finding study …
被引用次数：18 相关文章

Safety of rolapitant, a novel NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or …

L Urban, A Poma, M Motta Dardeno, RE Martell - 2014 - ascopubs.org
9636 Background: Rolapitant is a highly selective competitive long acting NK-1 receptor
antagonist that successfully achieved the primary endpoint of complete response (no emesis …
被引用次数：4 相关文章
[PDF] waocp.org

Efficacy and safety of neurokinin-1 receptor antagonists for prevention of chemotherapy-induced nausea and vomiting: systematic review and meta-analysis of …

DM Yuan, Q Li, Q Zhang, XW Xiao… - Asian Pacific Journal …, 2016 - journal.waocp.org
Objectives: Can addition of neurokinin-1 receptor antagonists (NK1-RAs) be considered as
an ideal strategy for the prevention of chemotherapy-induced nausea and vomiting (CINV) …
被引用次数：32 相关文章 所有 9 个版本
[HTML] sciencedirect.com

[HTML][HTML] Phase 3 (P04832) Trial Results for Rolapitant, a Novel Nk-1 Receptor Antagonist, in the Prevention of Chemotherapy-Induced Nausea and Vomiting (Cinv) in …

MR Chasen, A Poma, ML Hedley, R Martell, C Gridelli - Annals of Oncology, 2014 - Elsevier
Aim: Rolapitant is a highly selective competitive long acting NK-1 receptor antagonist that
demonstrated safety and prevention of CINV in both phase 2 and 3 trials. Methods: A multi …
被引用次数：3 相关文章 所有 2 个版本

Rolapitant for the treatment of chemotherapy-induced nausea and vomiting: a review of the clinical evidence

MR Chasen, BL Rapoport - Future Oncology, 2016 - Taylor & Francis
Chemotherapy-induced nausea and vomiting (CINV), both acute and delayed, has a
dramatic effect on the well-being and quality of life of patients with cancer. Improved …
被引用次数：18 相关文章 所有 4 个版本
[PDF] tandfonline.com

Differential pharmacology and clinical utility of rolapitant in chemotherapy-induced nausea and vomiting

BL Rapoport - Cancer Management and Research, 2017 - Taylor & Francis
Chemotherapy-induced nausea and vomiting (CINV) is a debilitating side effect of many
cytotoxic chemotherapy regimens. CINV typically manifests during two well-defined time …
被引用次数：13 相关文章 所有 11 个版本

Defining the efficacy of neurokinin-1 receptor antagonists in controlling chemotherapy-induced nausea and vomiting in different emetogenic settings—a meta-analysis

K Jordan, DG Warr, A Hinke, L Sun… - Supportive Care in Cancer, 2016 - Springer
Purpose This meta-analysis was performed to evaluate the efficacy of neurokinin-1 receptor
antagonists (NK1RAs) for the prevention of chemotherapy-induced nausea and vomiting …
被引用次数：23 相关文章 所有 8 个版本

The safety of rolapitant for the treatment of nausea and vomiting associated with chemotherapy

RM Navari - Expert Opinion on Drug Safety, 2019 - Taylor & Francis
Introduction: Chemotherapy-induced nausea and vomiting is a significant clinical issue that
affects patients' quality of life as well as treatment decisions. Significant improvements in the …
被引用次数：5 相关文章 所有 3 个版本